<p>Weekly alternate intensive regimen FIrB/FOx in metastatic colorectal cancer patients: an update from clinical practice</p>-Reference-Cited by-同舟云学术

Weekly alternate intensive regimen FIrB/FOx in metastatic colorectal cancer patients: an update from clinical practice

Published:2019-03 Issue: Volume:Volume 12 Page:2159-2170
ISSN:1178-6930
Container-title:OncoTargets and Therapy
language:en
Short-container-title:OTT

Author:

Cortellini Alessio^ORCID,Cannita Katia,Parisi Alessandro^ORCID,Lanfiuti Baldi Paola,Venditti Olga,D'Orazio Carla,Dal Mas Antonella,Calvisi Giuseppe,Giordano Aldo V.,Vicentini Vincenzo,Vicentini Roberto,Felicioni Lara,Marchetti Antonio,Buttitta Fiamma,Russo Antonio,Ficorella Corrado

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Oncology

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Primary versus secondary antiemetic prophylaxis with NK1 receptor antagonists in patients affected by gastrointestinal malignancies and treated with a doublet or triplet combination regimen including oxaliplatin and/or irinotecan plus fluoropyrimidines: A propensity score matched analysis;Frontiers in Oncology;2022-08-12

2. Concurrent RAS and RAS/BRAF V600E Variants in Colorectal Cancer: More Frequent Than Expected? A Case Report;Frontiers in Oncology;2022-04-07

3. Clinicians’ Attitude to Doublet Plus Anti-EGFR Versus Triplet Plus Bevacizumab as First-line Treatment in Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Patients: A Multicenter, “Real-Life”, Case-Control Study;Clinical Colorectal Cancer;2021-12

4. Determining lines of therapy in patients with solid cancers: a proposed new systematic and comprehensive framework;British Journal of Cancer;2021-04-13

5. What Is Known about Theragnostic Strategies in Colorectal Cancer;Biomedicines;2021-02-01